Application of bispecific antibody in preparation of medicine for treating cancer

Abstract

The invention provides an application of a bispecific antibody as an anti-cancer drug, especially an application of the bispecific antibody in preparation of a drug for treating advanced solid tumors.

Description

Technical Field

[0001] The present invention belongs to the field of medicine and relates to the use of a bispecific antibody in the preparation of a drug for treating cancer, wherein the bispecific antibody is a drug that simultaneously inhibits the dual targets of human epidermal growth factor receptor and tyrosine kinase Met. Based on its unique structure and new mechanism of action, the bispecific antibody has the potential to achieve clinical benefits that are difficult to achieve with a single drug or combination of drugs. Background Art

[0002] EGFR is a member of the human epidermal growth factor receptor (HER) family and is widely distributed on the surface of epithelial, mesenchymal and neuronal tissues or cells. Under physiological conditions, after binding to its ligand (such as epidermal growth factor EGF), it can promote cell differentiation, proliferation, migration and survival. Under pathological conditions, EGFR, as a pro-oncogene, can promote the occurrence and development of tumors through gene mutation, upregulation of expression, etc. Common EGFR gene mutation sites are exons 18-21, mainly exon 19 deletion (Exon 19del), exon 21 L858R point mutation (L858R), exon 20 insertion mutation (Exon20ins), etc. EGFR mutation or overexpression has a high incidence in NSCLC (50% mutation), head and neck cancer (80% overexpression), colon cancer (25% mutation) and breast cancer (11% overexpression / mutation). Several drugs targeting EGFR have been confirmed to be clinically effective in the above indications.

[0003] The MET gene is a proto-oncogene that encodes the mesenchymal epidermal transition factor (c-MET), also known as the hepatocyte growth factor receptor (HGFR). c-MET / HGFR also belongs to the receptor tyrosine kinase (RTK) family and is a transmembrane tyrosine kinase receptor. After binding to its ligand hepatocyte growth factor (HGF), it can induce MET dimerization and phosphorylation of its substrate, thereby activating downstream signaling pathways and participating in the regulation of cell proliferation, differentiation, migration, angiogenesis and other processes.

[0004] The c-MET pathway is closely related to EGFR resistance. MET gene expression bypasses the inhibited EGFR phosphorylation kinase pathway and provides a bypass pathway by activating ERBB3 and the PI3K / AKT pathway downstream of MET. MET activates and promotes downstream signal transduction through this bypass pathway, avoiding cell apoptosis caused by EGFR TKI, while promoting tumor cell proliferation, and ultimately leading to EGFR TKI resistance. Therefore, it is very necessary to inhibit the EGFR and c-MET pathways at the same time to overcome the EGFR TKI resistance caused by MET pathway activation, which provides a theoretical basis for the combined treatment of advanced solid tumors with c-MET pathway inhibition and EGFR pathway inhibition.

[0005] Due to the special mutation structure, EGFR Exon 20ins is insensitive to the existing first to third generation EGFR TKIs, and chemotherapy and immunotherapy are also ineffective. The first-line standard treatment recommended by the 2022 CSCO guidelines is still chemotherapy based on platinum drugs. There is currently no standard treatment for patients with advanced solid tumors with EGFR target resistance caused by c-MET pathway activation. Therefore, finding effective treatments is an urgent clinical need. Summary of the invention

[0006] The present invention provides use of a bispecific antibody specifically binding to c-Met and EGFR in preparing a drug for preventing or treating cancer.

[0007] The present invention also provides a use of a pharmaceutical composition of a bispecific antibody specifically binding to c-Met and EGFR in preparing a drug for preventing or treating cancer.

[0008] The present invention also provides a bispecific antibody that specifically binds to c-Met and EGFR, or a pharmaceutical composition of the bispecific antibody, and its use in combination with an EGFR inhibitor in the preparation of a drug for preventing or treating cancer.

[0009] In some embodiments, the EGFR inhibitor is selected from erlotinib, gefitinib, befotertinib, osimertinib, almonertinib, furmonertinib, oritinib, rezetinib, avitinib, olmutinib, rociletinib; preferably almonertinib and osimertinib.

[0010] In some embodiments, the bispecific antibody or bispecific antibody pharmaceutical composition and the EGFR inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously, concurrently, sequentially, continuously, alternately or separately.

[0011] In some embodiments, the above-mentioned bispecific antibody comprises a first antibody or antigen-binding fragment against a first target c-Met, and a second antibody or antigen-binding fragment against a second target EGFR; wherein the first antibody or antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO:01, HCDR2 as shown in SEQ ID NO:02, HCDR3 as shown in SEQ ID NO:03; and, LCDR1 as shown in SEQ ID NO:04, LCDR2 as shown in SEQ ID NO:05, LCDR3 as shown in SEQ ID NO:06; wherein the second antibody or antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO:09, HCDR2 as shown in SEQ ID NO:10, HCDR3 as shown in SEQ ID NO:11; and, LCDR1 as shown in SEQ ID NO:12, LCDR2 as shown in SEQ ID NO:13, LCDR3 as shown in SEQ ID NO:14.

[0012] In some embodiments, the above-mentioned bispecific antibody comprises a first antibody or antigen-binding fragment against a first target c-Met, and a second antibody or antigen-binding fragment against a second target EGFR, the first antibody or antigen-binding fragment comprising a heavy chain variable region as shown in SEQ ID NO:07, and a light chain variable region as shown in SEQ ID NO:08; the second antibody or antigen-binding fragment comprises a heavy chain variable region as shown in SEQ ID NO:15, and a light chain variable region as shown in SEQ ID NO:16.

[0013] In some embodiments, the c-Met binding domain of the bispecific antibody is a Fab region formed by a first heavy chain and a first light chain, the EGFR binding domain is a Fab region formed by a second heavy chain and a second light chain, and the first heavy chain and the second heavy chain bind to each other to form a heterodimer Fc region.

[0014] In some embodiments, the bispecific antibody comprises a first antibody or antigen-binding fragment against a first target c-Met, and a second antibody or antigen-binding fragment against a second target EGFR, the first antibody or antigen-binding fragment comprising a heavy chain as shown in SEQ ID NO:21 and a light chain as shown in SEQ ID NO:22; the second antibody or antigen-binding fragment comprises a heavy chain as shown in SEQ ID NO:23 and a light chain as shown in SEQ ID NO:24.

[0015] In some embodiments, the above-mentioned cancer is a cancer expressing c-Met and / or EGFR.

[0016] In some embodiments, the above-mentioned cancer is a cancer expressing c-Met.

[0017] In some embodiments, the above-mentioned cancer is a cancer expressing EGFR.

[0018] In some embodiments, the above-mentioned cancer is a cancer expressing c-Met and EGFR.

[0019] In some embodiments, the cancer expressing c-Met or / and EGFR is mediated by wild-type EGFR, EGFR activating mutations, EGFR gene amplification, elevated levels of circulating HGF, wild-type c-Met, c-Met activating mutations, c-Met gene amplification, MET gene amplification, or mutant KRAS, preferably mediated by EGFR activating mutations, MET gene amplification.

[0020] Exemplary EGFR activating mutations that may be associated with cancer include point mutations, deletion mutations, insertion mutations, inversions or gene amplifications that cause at least one biological activity of EGFR to increase (such as elevated tyrosine kinase activity, receptor homodimer and heterodimer formation, ligand binding enhancement, etc.). Mutations may be located in any portion of the regulatory region of the EGFR gene or associated with the EGFR gene, and include mutations in exons 18, 19, 20 or 21 or mutations in the kinase domain. Other examples of EGFR activating mutations are known in the art (see, e.g., U.S. Patent Publication US2005 / 0272083). Information about EGFR and other ErbB receptors (including receptor homodimers and heterodimers, receptor ligands, autophosphorylation sites, and signal transduction molecules involved in ErbB-mediated signal transduction) is known in the art (see, e.g., Hynes and Lane, Nature Reviews Cancer 5: 341-354, 2005).

[0021] In some embodiments, the cancer is a cancer expressing EGFR or / and c-Met mediated by an EGFR activating mutation. In some embodiments, the EGFR activating mutation comprises at least one mutation selected from the group consisting of: G719X (X is any amino acid), L861X (X is any amino acid).

[0022] In some embodiments, the EGFR activating mutation comprises at least one mutation selected from the group consisting of: L718Q, L718V, G719A, G719S, G719C, G719D, L858R, L858P, L861Q, G724S, E746K, L747S, E749Q, A750P, A755V, V765M, C797S, S768I, or T790M substitution; deletion of E746-A750; deletion of R748-P753; insertion of Ala (A) between M766 and A767; insertion of Ser, Val, and Ala (SVA) between S768 and V769; Asn and Ser (NS) between P772 and H773 insertion of one or more amino acids between D761 and E762, between A763 and Y764, between Y764 and Y765, between M766 and A767, between A767 and V768, between S768 and V769, between V769 and D770, between D770 and N771, between N771 and P772, between P772 and H773, between H773 and V774, between V774 and C775; deletion of one or more amino acids in EGFR exon 19; or insertion of one or more amino acids in EGFR exon 19; one or more deletions in EGFR exon 20; or one or more insertions in EGFR exon 20; or any combination thereof.

[0023] In some embodiments, the EGFR activating mutation comprises at least one mutation selected from the group consisting of: L858R mutation, T790M mutation, L861Q mutation, one or more insertion mutations in EGFR exon 20, and one or more amino acid deletion mutations in EGFR exon 19.

[0024] In some embodiments, the above cancer is selected from solid tumors, preferably advanced solid tumors.

[0025] In some embodiments, the cancer is selected from epithelial cell cancer, breast cancer, ovarian cancer, lung cancer, rectal cancer, anal cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, pharyngeal cancer, nasal cancer, pancreatic cancer, skin cancer, oral cancer, tongue cancer, esophageal cancer, vaginal cancer, endometrial cancer, cervical cancer, spleen cancer, testicular cancer, gastric cancer, thymus cancer, colon cancer, thyroid cancer, liver cancer or melanoma, preferably lung cancer or liver cancer.

[0026] In some embodiments, the cancer is selected from non-small cell lung cancer (NSCLC), lung adenocarcinoma, lung squamous cell carcinoma, large cell lung cancer, small cell lung cancer, sarcomatoid carcinoma of the lung, hepatocellular carcinoma (HCC).

[0027] In a preferred embodiment, the above cancer is selected from non-squamous non-small cell lung cancer. In a preferred embodiment, the cancer is selected from locally advanced or metastatic non-squamous non-small cell lung cancer.

[0028] In a preferred embodiment, the above-mentioned cancer is selected from locally advanced or metastatic non-small cell lung cancer, carrying an EGFR activating mutation including at least one mutation selected from the following group: L858R mutation, T790M mutation, L861Q mutation, C797S mutation, one or more insertion mutations in EGFR exon 20, and one or more amino acid deletion mutations in EGFR exon 19.

[0029] In a preferred embodiment, the above-mentioned cancer is selected from locally advanced or metastatic non-squamous non-small cell lung cancer, carrying an EGFR activating mutation including at least one mutation selected from the following group: L858R mutation, one or more insertion mutations in EGFR exon 20, and one or more amino acid deletion mutations in EGFR exon 19.

[0030] In a preferred embodiment, the above cancer is selected from locally advanced or metastatic non-squamous non-small cell lung cancer comprising a deletion mutation of one or more amino acids in exon 19 of EGFR or a L858R mutation.

[0031] In a preferred embodiment, the above cancer is selected from locally advanced or metastatic non-small cell lung cancer comprising one or more insertion mutations in exon 20 of EGFR.

[0032] In some embodiments, the dosage of the above-mentioned EGFR inhibitor is 10-500 mg, preferably 10-200 mg, and more preferably 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg.

[0033] In some embodiments, the EGFR inhibitor is administered twice a day, once a day, once every two days, or once every three days, preferably once a day or once every two days.

[0034] In a preferred embodiment, the EGFR inhibitor is administered in a dosage of 110 mg and the administration frequency is once a day.

[0035] The bispecific anti-EGFR / c-Met antibody can be administered in a pharmaceutically acceptable excipient, diluent or carrier.

[0036] "Carrier" refers to a diluent, adjuvant, excipient or vehicle with which the antibody of the invention is administered. Such vehicles can be liquids, such as water and oils, including those derived from petroleum, animals, plants or synthetic oils, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. For example, 0.4% saline and 0.3% glycine can be used to formulate bispecific anti-EGFR / c-Met antibodies. These solutions are sterile and generally free of particulate matter. They can be sterilized by conventional, well-known sterilization techniques (e.g., filtration). For parenteral administration, the carrier may include sterile water, and other excipients may be added to increase solubility or preservatives. Injectable suspensions or solutions can also be prepared using aqueous carriers together with suitable additives. Suitable vehicles and formulations include other human proteins (e.g., human serum albumin).

[0037] In some embodiments, the bispecific antibody composition unit concentration is about 1 mg / mL to about 100 mg / mL, preferably about 5 mg / mL to about 50 mg / mL, and more preferably about 10 mg / mL to about 30 mg / mL.

[0038] In some embodiments, the bispecific antibody pharmaceutical composition unit concentration is about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL.

[0039] In some embodiments, the specifications of the bispecific antibody pharmaceutical composition are 10 mL: 10 mg to 10 mL: 1000 mg per vial, preferably 10 mL: 100 mg to 10 mL: 500 mg, more preferably 10 mL: 100 mg, 10 mL: 200 mg, 10 mL: 300 mg, 10 mL: 400 mg, 10 mL: 500 mg.

[0040] The administration mode can be any suitable route for delivering the bispecific anti-EGFRxc-Met antibody to the host, such as parenteral administration, for example, intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, vaginal, rectal), using tablets, capsules, solutions, powders, gels, granules; and contained in syringes, implants, osmotic pumps, boxes, mini pumps; or other means well known in the art as understood by the skilled person. Site-specific administration can be achieved, for example, by the following means: intratumoral, parenteral, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracavitary, intracerebellar, intraventricular, intracolonic, intracervical, intragastric, intrahepatic, intracardiac, intraosseous, intrapelvic, intrapericardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravascular, intravesical, intralesional, vaginal, rectal, oral, sublingual, intranasal or transdermal delivery.

[0041] In some embodiments, the bispecific anti-EGFR / c-Met antibody or pharmaceutical composition thereof is administered at a dose of between about 100 mg to about 5000 mg.

[0042] In some embodiments, the bispecific anti-EGFR / c-Met antibody or pharmaceutical composition thereof is administered at a dose of between about 400 mg to about 2000 mg.

[0043] In some embodiments, the bispecific anti-EGFR / c-Met antibody or pharmaceutical composition thereof is administered at about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg g, about 710mg, about 720mg, about 730mg, about 740mg, about 750mg, about 760mg, about 770mg, about 780mg, about 790mg, about 800mg, about 810mg, about 820mg, about 830mg, about 840mg, about 850mg, about 860mg, about 870mg, about 880mg, about 890mg, about 900mg, about 910mg, about 920mg, about 930mg, about 940mg, about 950mg, about 960mg, about 970mg, about 980mg, about 990mg, about 1000mg, about 1010mg, about 1020mg, about 1030mg, about 1040mg, about 105 0mg, about 1060mg, about 1070mg, about 1080mg, about 1090mg, about 1100mg, about 1110mg, about 1120mg, about 1130mg, about 1140mg, about 1150mg, about 1160mg, about 1170mg, about 1180mg, about 1190mg, about 1200mg, about 1210mg, about 1220mg, about 1230mg, about 1240mg, about 1250mg, about 1260mg, about 1270mg, about 1280mg, about 1290mg, about 1300mg, about 1310mg, about 1320mg, about 1330mg, about 1340mg, about 1350mg, about 1360 mg, about 1370mg, about 1380mg, about 1390mg, about 1400mg, about 1410mg, about 1420mg, about 1430mg, about 1440mg, about 1450mg, about 1460mg, about 1470mg, about 1480mg, about 1490mg, about 1500mg, about 1510mg, about 1520mg, about 1530mg, about 1540mg, about 1550mg, about 1560mg, about 1570mg, about 1580mg, about 1590mg, about 1600mg, about 1610mg, 1620mg, about 1630mg, about 1640mg, about 1650mg, about 1660mg, about 1670mg,About 1680 mg, about 1690 mg, about 1700 mg, about 1710 mg, about 1720 mg, about 1730 mg, about 1740 mg, about 1750 mg, about 1760 mg, about 1770 mg, about 1780 mg, about 1790 mg, about 1800 mg, about 1810 mg, about 1820 mg, about 1830 mg, about 1840 mg, about 1850 mg, about 1860 mg, about 1870 mg, about 1880 mg, 1890 mg, about 1900 mg, about 1910 mg, about 1920 mg, about 1930 mg, about 1940 mg, about 1950 mg, about 1960 mg, about 1970 mg, about 1980 mg, about 1990 mg or about 2000 mg.

[0044] In a preferred embodiment, the above-mentioned bispecific anti-EGFR / c-Met antibody or pharmaceutical composition thereof is administered at a dose of 400 mg, 800 mg, 1000 mg, 1200 mg, 1400 mg, 1600 mg, 1800 mg, or 2000 mg.

[0045] In a preferred embodiment, the above-mentioned bispecific anti-EGFR / c-Met antibody or pharmaceutical composition thereof is administered at a dose of 400 mg, 800 mg, 1200 mg, 1600 mg, or 2000 mg.

[0046] In some embodiments, the bispecific anti-EGFR / c-Met antibody or a pharmaceutical composition thereof is administered once daily. In some embodiments, the bispecific anti-EGFR / c-Met antibody or a composition thereof is administered once every two days. In some embodiments, the bispecific anti-EGFR / c-Met antibody or a composition thereof is administered once every three days. In some embodiments, the bispecific anti-EGFR / c-Met antibody or a composition thereof is administered twice a week. In some embodiments, the bispecific anti-EGFR / c-Met antibody or a composition thereof is administered once a week. In some embodiments, the bispecific anti-EGFR / c-Met antibody or a composition thereof is administered once every two weeks. In some embodiments, the bispecific anti-EGFR / c-Met antibody or a composition thereof is administered once every three weeks. In some embodiments, the bispecific anti-EGFR / c-Met antibody or a composition thereof is administered once a month.

[0047] In a preferred embodiment, the bispecific anti-EGFR / c-Met antibody or pharmaceutical composition thereof is administered once a week in the first treatment cycle and once every two weeks thereafter, with every four weeks being one treatment cycle.

[0048] In a preferred embodiment, the bispecific anti-EGFR / c-Met antibody or pharmaceutical composition thereof is administered once a week in the first treatment cycle and once every three weeks thereafter, with each three weeks being one treatment cycle.

[0049] In a preferred embodiment, the bispecific anti-EGFR / c-Met antibody or its pharmaceutical composition is administered at a dose of 400 mg, 800 mg, 1200 mg, 1600 mg, or 2000 mg; the dosing frequency is once a week in the first treatment cycle, once every two weeks starting from the second treatment cycle, and every four weeks is a treatment cycle.

[0050] The present invention provides a method for treating or preventing cancer, which comprises administering the above-mentioned bispecific antibody or bispecific antibody pharmaceutical composition to a subject in need thereof.

[0051] The present invention provides a method for treating or preventing cancer, which comprises administering the above-mentioned bispecific antibody or bispecific antibody pharmaceutical composition and the above-mentioned EGFR inhibitor in combination to a subject in need thereof, wherein the combined administration may be simultaneous, concurrent, sequential, continuous, alternating or separate administration.

[0052] In some embodiments, the above-mentioned cancer is a solid tumor, preferably epithelial cell cancer, breast cancer, ovarian cancer, lung cancer, rectal cancer, anal cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, pharyngeal cancer, nasal cancer, pancreatic cancer, skin cancer, oral cancer, tongue cancer, esophageal cancer, vaginal cancer, endometrial cancer, cervical cancer, spleen cancer, testicular cancer, gastric cancer, thymic cancer, colon cancer, thyroid cancer, liver cancer or melanoma, more preferably non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, large cell lung cancer, small cell lung cancer, lung sarcoma-like cancer, hepatocellular carcinoma.

[0053] In a preferred embodiment, the cancer is locally advanced or metastatic non-small cell lung cancer, preferably locally advanced or metastatic non-small cell lung cancer with EGFR mutation.

[0054] In some embodiments, the above-mentioned EGFR mutation includes at least one mutation selected from the following group: L858R mutation, T790M mutation, L861Q mutation, C797S mutation, one or more insertion mutations in EGFR exon 20, and one or more amino acid deletion mutations in EGFR exon 19.

[0055] In a preferred embodiment, the cancer is non-small cell lung cancer with a deletion mutation of one or more amino acids in exon 19 of EGFR or a L858R mutation.

[0056] The results of in vitro pharmacodynamic tests showed that the bispecific anti-EGFRxc-Met antibody of the present invention or its composition can bind to cynomolgus monkey EGFR and c-MET, and enhanced ADCC activity can be detected. The results of in vivo pharmacodynamic tests showed that the anti-tumor effect of the bispecific anti-EGFRxc-Met of the present invention is better than that of Amivantamab, a similar drug that has been marketed. The anti-tumor effect of the bispecific anti-EGFRxc-Met of the present invention combined with osimertinib is significantly stronger than that of the two single drugs, showing a good combined synergistic effect; no new toxicity was observed in the animals in the combined drug administration group. All animals in the EGFR triple mutation and EGFR-20 exon insertion mutation tumor models were well tolerated and the growth of tumors was well inhibited. It has biological activity and therapeutic potential for the treatment of advanced malignant tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 .Quality identification results of the bispecific antibody EGFRxc-Met-1. 1A shows the purity of the bispecific antibody obtained by affinity purification, and 1B shows the proportion of the correctly paired products of the purified bispecific antibody.

[0058] Figure 2 .Effect of the combination of bispecific antibody EGFRxc-Met-1 and ametinib on the growth of subcutaneous xenograft tumors in PC-9 nude mice. DETAILED DESCRIPTION DETAILED DESCRIPTION OF THE INVENTION

[0060] 1. Terminology

[0061] In order to make the present application more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present application belongs.

[0062] When a list is provided, it is understood that each individual element in the list and each combination of the list is a separate embodiment unless otherwise indicated. For example, a list of embodiments presented as "A, B, or C" will be understood to include embodiments "A," "B," "C," "A or B," "A or C," "B or C," or "A, B, or C."

[0063] "About" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. In the context of a particular assay, result, or embodiment, unless otherwise expressly stated in the examples or elsewhere in the specification, "about" means within one standard deviation or up to a range of 5%, whichever is greater, as is customary in the art.

[0064] The three letter codes and one letter codes for amino acids used herein are as described in J. Biol. Chem, 243, p3558 (1968).

[0065] The term "antibody" as used herein refers to immunoglobulins, which are tetrapeptide chains consisting of two identical heavy chains and two identical light chains connected by interchain disulfide bonds. The amino acid composition and arrangement order of the constant region of the immunoglobulin heavy chain are different, so their antigenicity is also different. Based on this, immunoglobulins can be divided into five categories, or isotypes of immunoglobulins: Type, that is IgM, IgD, IgG, IgA and IgE, their corresponding heavy chains are μ chain, δ chain, γ chain, α chain and ε chain respectively. The same class of Ig can be divided into different subclasses according to the difference in the amino acid composition of the hinge region and the number and position of the disulfide bonds of the heavy chain. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. The light chain is divided into κ chain or λ chain according to the difference in the constant region. Each of the five classes of Ig can have κ chain or λ chain.

[0066] In the present application, the antibody light chain variable region described in the present application may further comprise a light chain constant region, wherein the light chain constant region comprises a human or mouse κ, λ chain or a variant thereof.

[0067] In the present application, the antibody heavy chain variable region described in the present application may further include a heavy chain constant region, and the heavy chain constant region includes human or mouse IgG1, IgG2, IgG 3, IgG 4 or variants thereof.

[0068] The sequences of about 110 amino acids near the N-terminus of the antibody heavy and light chains vary greatly, which is the variable region (V region); the remaining amino acid sequences near the C-terminus are relatively stable, which is the constant region (C region). The variable region includes three hypervariable regions (HVRs) and four relatively conservative framework regions (FRs). The three hypervariable regions determine the specificity of the antibody, also known as the complementarity determining regions (CDRs). Each light chain variable region (VL) and heavy chain variable region (VH) consists of three CDR regions and four FR regions, arranged in the order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3. The number and position of the CDR amino acid residues in the VL and VH regions of the antibodies or antigen-binding fragments described in the present application conform to the known Kabat numbering convention and the Kabat or ABM definition convention (http: / / bioinf.org.uk / abs / ).

[0069] The term "EGFR" as described in this application refers to human epidermal growth factor receptor 1, also known as ErbB-1 or HER1. EGFR is a receptor tyrosine kinase comprising an extracellular ligand binding domain, a membrane-spanning domain, and an intracellular kinase domain. After binding to its ligand (e.g., epidermal growth factor (EGF) and transforming growth factor α (TGFα)), EGFR forms homodimers or heterodimers with other ErbB receptors, and its kinase function is activated, resulting in autophosphorylation of several tyrosines in the intracellular domain. Anti-EGFR antibodies are antibodies that can specifically bind to EGFR. In a specific embodiment, anti-EGFR antibodies can interfere with or inhibit the activation of EGFR, for example, by preventing ligand binding and / or receptor dimerization. After activation, EGFR can transmit signals to downstream effectors, including PI3-K, RAS-RAF-MAPK P44 / P42 and protein kinase C signaling pathways, and ultimately transmit signals to the cell nucleus to regulate cell proliferation.

[0070] The term "EGFR exon 20 insertion mutation" or "EGFR exon 20 mutation", or "EGFR Exon 20ins" or "Exon20ins" as described in the present application refers to a mutation comprising at least one insertion or duplication of bases at amino acids 762 to 823 of human EGFR. EGFR exon 20 insertion mutations can be detected using known methods, such as sequencing, including next generation sequencing (NGS), fluorescent in situ hybridization, immunohistochemistry, flow cytometry, or Western blotting.

[0071] "Cancer expressing EGFR and / or c-Met" refers to a cancer with detectable EGFR and / or c-Met expression or with EGFR and / or c-Met mutation or amplification. EGFR or c-Met expression, amplification and mutation status can be detected using known methods, such as sequencing, including next generation sequencing, fluorescent in situ hybridization, immunohistochemistry, flow cytometry or Western blot.

[0072] The term "recombinant human antibody" includes human antibodies prepared, expressed, created or isolated by recombinant methods, and the techniques and methods involved are well known in the art, such as:

[0073] 1. Antibodies isolated from transgenic, transchromosomal animals (e.g., mice) expressing human immunoglobulin genes or hybridomas prepared therefrom;

[0074] 2. Antibodies isolated from host cells transformed to express antibodies, such as transfectomas;

[0075] 3. Antibodies isolated from a recombinant combinatorial human antibody library; and

[0076] 4. Antibodies prepared, expressed, created or isolated by methods such as splicing human immunoglobulin gene sequences to other DNA sequences.

[0077] Such recombinant human antibodies contain variable and constant regions that utilize specific human germline immunoglobulin sequences encoded by the germline genes, but also include subsequent rearrangements and mutations that occur, such as during antibody maturation.

[0078] The term "humanized antibody", also known as CDR-grafted antibody, refers to an antibody produced by transplanting mouse CDR sequences into the human antibody variable region framework. Humanized antibodies can overcome the disadvantage of chimeric antibodies that they carry a large amount of mouse protein components, thereby inducing a strong immune response. In order to avoid a decrease in activity while reducing immunogenicity, the human antibody variable region can be subjected to minimal reverse mutations to maintain activity.

[0079] The term "antigen-binding fragment" refers to an antigen-binding fragment of an antibody and antibody analogs, which generally include at least a portion of the antigen-binding region or variable region (e.g., one or more CDRs) of a parental antibody. Antibody fragments retain at least some of the binding specificity of the parental antibody. Typically, when activity is expressed on a molar basis, antibody fragments retain at least 10% of the parental binding activity. Preferably, antibody fragments retain at least 20%, 50%, 70%, 80%, 90%, 95% or 100% or more of the binding affinity of the parental antibody to the target. Examples of antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv fragments, linear antibodies, single-chain antibodies, nanobodies, domain antibodies, and multispecific antibodies. Engineered antibody variants are reviewed in Holliger and Hudson, 2005, Nat. Biotechnol. 23: 1126-11.

[0080] The "Fab fragment" consists of a light chain and the CH1 and variable region of a heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.

[0081] The "Fc" region contains two heavy chain fragments comprising the CH1 and CH2 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by the hydrophobic interaction of the CH3 domain.

[0082] A "Fab' fragment" contains one light chain and a portion of one heavy chain including the VH domain and the CH1 domain and the region between the CH1 and CH2 domains, whereby an interchain disulfide bond can be formed between the two heavy chains of the two Fab' fragments to form a F(ab')2 molecule.

[0083] A "F(ab')2 fragment" contains two light chains and two heavy chains comprising a portion of the constant region between the CH1 and CH2 domains, whereby an interchain disulfide bond is formed between the two heavy chains. Thus, a F(ab')2 fragment consists of two Fab' fragments held together by a disulfide bond between the two heavy chains.

[0084] The "Fv region" comprises the variable regions from both the heavy and light chains, but lacks the constant regions.

[0085] The term "multispecific antibody" is used in its broadest sense to cover antibodies with multiple epitope specificities. These multispecific antibodies include, but are not limited to: antibodies comprising a heavy chain variable region VH and a light chain variable region VL, wherein the VH-VL unit has multiple epitope specificities; antibodies having two or more VL and VH regions, each VH-VL unit binding to a different target or a different epitope of the same target; antibodies having two or more single variable regions, each single variable region binding to a different target or a different epitope of the same target; full-length antibodies, antibody fragments, diabodies, bispecific diabodies and triabodies, antibody fragments covalently or non-covalently linked together, etc.

[0086] The term "single-chain antibody" is a single-chain recombinant protein formed by connecting the heavy chain variable region VH and the light chain variable region VL of an antibody through a connecting peptide. It is the smallest antibody fragment with a complete antigen binding site.

[0087] The term "domain antibody fragment" is an immunologically functional immunoglobulin fragment containing only the heavy chain variable region or the light chain variable region chain. In some cases, two or more VH regions are covalently linked with a peptide linker to form a bivalent domain antibody fragment. The two VH regions of the bivalent domain antibody fragment can target the same or different antigens.

[0088] The term "single-arm antibody" as described in the present application refers to an antigen-binding fragment comprising a Fab segment and an Fc segment, wherein the Fab segment generally comprises a heavy chain (e.g., VH and CH1) and a light chain (e.g., VL and CL), and the Fc segment comprises a constant region (e.g., CH2 and CH3). The Fab segment and the Fc segment may be connected by a joint or not by a joint. The single-arm antibody of the present invention may be prepared or synthesized by a variety of methods, for example, by constructing a sequence encoding a Fab heavy chain and a sequence encoding an Fc into the same vector, and constructing a sequence encoding a Fab light chain into another vector, and transforming the two vectors into host cells, respectively, to obtain a single-arm antibody.

[0089] The term "antigen binding site" of the present application refers to the three-dimensional site recognized by the antibody or antigen binding fragment of the present application.

[0090] The term "epitope" refers to a site on an antigen that specifically binds to an immunoglobulin or antibody. An epitope can be formed by adjacent amino acids, or non-adjacent amino acids juxtaposed by tertiary folding of a protein. Epitopes formed by adjacent amino acids are usually retained after exposure to a denaturing solvent, while epitopes formed by tertiary folding are usually lost after treatment with a denaturing solvent. An epitope usually includes at least 3-15 amino acids in a unique spatial conformation. Methods for determining what epitope is bound by a given antibody are well known in the art, including immunoblotting and immunoprecipitation detection analysis, etc. Methods for determining the spatial conformation of an epitope include techniques in the art and techniques described herein, such as X-ray crystallography and two-dimensional nuclear magnetic resonance, etc.

[0091] The terms "specific binding" and "selective binding" used in this application refer to the binding of an antibody to an epitope on a predetermined antigen. Generally, when human EGFR or c-Met is used as an analyte and an antibody is used as a ligand, the antibody is detected by surface plasmon resonance (SPR) technology in an instrument with a specific binding of less than 10 -7 M or even smaller equilibrium dissociation constant (K D ) binds to a predetermined antigen, and its affinity for binding to the predetermined antigen is at least twice its affinity for binding to a non-specific antigen (such as BSA, etc.) other than the predetermined antigen or a closely related antigen. The term "antibody that recognizes an antigen" can be used interchangeably with the term "specific binding antibody" herein.

[0092] The terms "inhibit" or "block" are used interchangeably and encompass both partial and complete inhibition / blocking. Inhibition / blocking of a ligand preferably reduces or alters the normal level or type of activity that occurs when ligand binding occurs without inhibition or blocking. Inhibition and blocking are also intended to include any measurable reduction in ligand binding affinity when in contact with the antibody compared to the ligand not in contact with the antibody.

[0093] The term "inhibiting growth" (eg, with respect to cells) is intended to include any measurable decrease in cell growth.

[0094] The terms "induce an immune response" and "enhance an immune response" are used interchangeably and refer to the stimulation of an immune response (ie, passive or adaptive) to a specific antigen. The term "induce" with respect to inducing CDC or ADCC refers to the stimulation of a specific direct cell killing mechanism.

[0095] The "ADCC" mentioned in this application, namely antibody-dependent cell-mediated cytotoxicity, refers to the direct killing of target cells coated with antibodies by cells expressing Fc receptors through recognition of the Fc segment of antibodies. The ADCC effector function of antibodies can be enhanced, reduced, reduced or eliminated by modifying the Fc segment on IgG. The modification refers to mutations in the heavy chain constant region of antibodies.

[0096] Methods for producing and purifying antibodies and antigen-binding fragments are well known and can be found in the prior art, such as the Cold Spring Harbor Manual of Antibody Laboratory Techniques, Chapters 5-8 and 15. For example, mice can be immunized with human BCMA or fragments thereof, and the resulting antibodies can be renatured, purified, and amino acid sequenced using conventional methods. Antigen-binding fragments can also be prepared using conventional methods. The antibodies or antigen-binding fragments described in the invention use genetic engineering methods to add one or more human FR regions to the non-human CDR region. Human FR germline sequences can be obtained from the ImMunoGeneTics (IMGT) website http: / / imgt.cines.fr, or from the Journal of Immunoglobulins, 2001 ISBN012441351.

[0097] The engineered antibodies or antigen-binding fragments of the present application can be prepared and purified by conventional methods. The cDNA sequence of the corresponding antibody can be cloned and recombined into a GS expression vector. The recombinant immunoglobulin expression vector can be stably transfected into CHO cells. As a more preferred prior art, mammalian expression systems can lead to glycosylation of antibodies, especially in F C The highly conserved N-terminal region. Stable clones are obtained by expressing antibodies that specifically bind to human antigens. Positive clones are expanded in serum-free culture medium in bioreactors to produce antibodies. The culture fluid that secretes antibodies can be purified and collected by conventional techniques. Antibodies can be filtered and concentrated by conventional methods. Soluble mixtures and polymers can also be removed by conventional methods, such as molecular sieves and ion exchange. The obtained product needs to be frozen immediately, such as -70°C, or freeze-dried.

[0098] The term "pharmaceutical composition" is a product comprising one or more active ingredients (e.g., antibodies, small molecule drugs) in optionally specific amounts, as well as any product produced directly or indirectly by combining one or more active ingredients in optionally specific amounts. The different active ingredients in the pharmaceutical composition can be independently administered in separate formulations, including administration simultaneously or at different time points to enhance synergy. In the present disclosure, "pharmaceutical composition" and "preparation" are not mutually exclusive.

[0099] The term "combination" or "combination" is a mode of administration, which refers to the administration of at least one dose of a bispecific antibody or a bispecific antibody pharmaceutical composition and at least one dose of an additional therapeutic agent within a certain time limit, wherein both substances show pharmacological effects. The time limit can be within a dosing cycle, preferably within 4 weeks, within 3 weeks, within 2 weeks, within 1 week, or within 24 hours, more preferably within 12 hours. The bispecific antibody or bispecific antibody pharmaceutical composition and the additional therapeutic agent can be administered simultaneously or sequentially. This period includes such treatment, wherein the bispecific antibody or bispecific antibody pharmaceutical composition and the additional therapeutic agent are administered by the same administration route or different administration routes. The combined administration mode described in the present application is selected from simultaneous administration, independent formulation and co-administration, or independent formulation and sequential administration.

[0100] The terms "administering," "giving," and "treating," when applied to an animal, a human, an experimental subject, a cell, a tissue, an organ, or a biological fluid, refer to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, a human, a subject, a cell, a tissue, an organ, or a biological fluid. "Administering," "giving," and "treating" may refer to, for example, treatment, pharmacokinetics, diagnosis, research, and experimental procedures. Treatment of cells includes contact of an agent with a cell, and contact of an agent with a fluid, wherein the fluid is in contact with the cell. "Administering," "giving," and "treating" also mean in vitro and ex vivo treatment of, for example, a cell, by an agent, a diagnosis, a combination composition, or by another cell. "Treatment," when applied to a human, veterinary, or research subject, refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.

[0101] The term "treatment" means administering an internal or external therapeutic agent, such as any of the antibodies of the present application, to a patient who has one or more symptoms of a disease, and it is known that the therapeutic agent has a therapeutic effect on these symptoms. Typically, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of a disease in the treated patient or population, whether by inducing regression of such symptoms or inhibiting the development of such symptoms to any clinically measured extent. The amount of the therapeutic agent that effectively alleviates any specific disease symptom (also referred to as a "therapeutically effective amount") may vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect in the patient. Whether the disease symptoms have been alleviated can be evaluated by any clinical detection method commonly used by doctors or other professional health care personnel to evaluate the severity or progression of the symptom. Although the embodiments of the present application (e.g., treatment methods or products) may not be effective in alleviating the target disease symptoms in every patient, they should alleviate the target disease symptoms in a statistically significant number of patients as determined by any statistical test known in the art, such as Student's t-test, chi-square test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test.

[0102] The term "preventing" a disease or disorder means preventing the disorder from occurring in a subject.

[0103] The term "diagnosis" refers to a method of determining whether a subject has a given disease or condition, or is likely to develop a given disease or condition in the future, or is likely to respond to treatment for a previously diagnosed disease or condition (i.e., to stratify a patient population according to likelihood of response to treatment). Diagnosis is typically performed by a physician based on general guidelines for the disease to be diagnosed or other criteria indicating that a subject is likely to respond to a particular treatment.

[0104] The term "consisting essentially of" or variations thereof as used throughout the specification and claims means including all recited elements or groups of elements, and optionally including other elements of similar or different properties to the recited elements, which other elements do not significantly alter the basic or novel properties of a specified dosing regimen, method, or composition.

[0105] The term "naturally occurring" as applied to an object as described herein refers to the fact that the object can be found in nature. For example, a polypeptide sequence or polynucleotide sequence that exists in an organism (including a virus) that can be isolated from a source in nature and has not been intentionally modified by humans in a laboratory is naturally occurring.

[0106] The term "effective amount" encompasses an amount sufficient to ameliorate or prevent the symptoms or symptoms of a medical condition. An effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the method, route and dosage of administration, and the severity of side effects. An effective amount may be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.

[0107] The term "exogenous" refers to substances produced outside the body of an organism, cell, or human body, depending on the context.

[0108] The term "endogenous" refers to a substance that is produced within a cell, organism or human body on a background basis.

[0109] The term "homology" refers to the sequence similarity between two polynucleotide sequences or between two polypeptides. When the positions in the two compared sequences are occupied by the same base or amino acid monomer subunit, for example, if every position of the two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The homology percentage between the two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared × 100%. For example, when the sequences are optimally aligned, if 6 out of 10 positions in the two sequences are matched or homologous, then the two sequences are 60% homologous. In general, comparison is performed when the two sequences are aligned to obtain the maximum homology percentage.

[0110] As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably, and all such names include progeny thereof. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It should also be understood that all progeny may not be exactly identical in terms of DNA content, due to intentional or unintentional mutations. Mutant progeny having the same function or biological activity as screened for in the originally transformed cell are included. Where different names are intended, this is clear from the context.

[0111] "Optional" or "optionally" means that the event or environment described later can but does not have to occur, and the description includes occasions where the event or environment occurs or does not occur. For example, "optionally comprising 1-3 antibody heavy chain variable regions" means that the antibody heavy chain variable region of a specific sequence can but does not have to be present. DETAILED DESCRIPTION

[0113] The following examples are used to further describe the present application, but these examples are not intended to limit the scope of the present application. Experimental methods in the examples of the present application that do not specify specific conditions are usually carried out according to conventional conditions, such as the Cold Spring Harbor Antibody Technology Laboratory Manual and the Molecular Cloning Manual; or according to the conditions recommended by the raw material or product manufacturer. Reagents that do not specify specific sources are conventional reagents purchased from the market.

[0114] Example 1. Construction and preparation of bispecific antibodies

[0115] Screening of monoclonal antibodies

[0116] The sequence of the anti-c-MET antibody-1 used in the present application was obtained by immunizing mice with the mesenchymal epidermal transition factor (c-MET) antigen (purchased from AcroBiosystems), extracting total RNA and performing reverse transcription, and screening the yeast display library constructed by PCR amplification. The sequence of antibody-1 was obtained by sequencing, wherein the CDR sequence of the antibody was determined by the IMGT numbering system (Lefrancet al., Dev. Comparat. Immunol. 27: 55-77, 2003).

[0117] Specifically, we first constructed a fully humanized anti-c-MET antibody library from five immunized mice with a diversity of 3×10^7, and labeled the human c-MET protein according to the product instructions of the biotin labeling kit (purchased from Thermo). Yeast that can specifically bind to c-MET was enriched by MACS, and yeast cells that specifically bind to the biotin-labeled c-MET protein with high affinity were finally obtained after multiple rounds of flow sorting. The sequences of the heavy and light chains of the antibody were retrieved using the yeast finally sorted as a template, and constructed into an expression vector to prepare the antibody.

[0118] Table 1. cMET antibody-1 sequence information

[0119]

[0120] After antibody preparation, the ForteBio affinity assay was performed according to the reported method (Estep, P et al., Antibody-antigen affinity and epitope binding assay based on high-throughput method. MAbs, 2013.5(2): p.270-8). The results showed that anti-c-MET antibody-1 had good binding activity with human c-MET protein and monkey c-MET protein.

[0121] Table 2. Affinity of candidate molecules for human c-Met

[0122] serial number KD(M) Kon(1 / Ms) Koff(1 / s) c-MET Antibody-1 2.93E-11 2.29E+05 6.71E-06

[0123] Table 3. Affinity of candidate molecules to monkey c-Met

[0124] serial number KD(M) Kon(1 / Ms) Koff(1 / s) c-MET Antibody-1 1.16E-09 3.69E+05 4.26E-04

[0125] Construction of anti-cMet and EGFR dual antibodies

[0126] According to the method described in the patent (patent application number: 201611016435.0), nucleotide sequences encoding the variable regions of anti-EGFR and anti-cMet antibodies were synthesized and linked to the constant regions that can spontaneously form heterodimers. Among them, the anti-cMet antibody is the c-MET antibody-1 obtained by the above screening, and the heavy chain variable region and light chain variable region of the anti-EGFR antibody are disclosed in patent number: WO02 / 100348, wherein the first amino acid Q in the heavy chain variable region is mutated to E, and the first amino acid A in the light chain variable region is mutated to D, and the specific sequences are shown in Table 4.

[0127] Table 4. EGFR antibody sequence information

[0128]

[0129] Using CH1 / CL preference mutation (patent number: WO2021 / 067404A2) and Knob in Hole technology, EGFRxcMET-1 molecules were constructed, and the heavy chain variable regions of anti-cMet antibody and anti-EGFR antibody were respectively constructed into the CH1 mutant heavy chain constant region CH SET1 (SEQ NO: 17) and CH SET2 (SEQ NO: 18); the light chain variable regions of anti-cMet antibody and anti-EGFR antibody were respectively constructed into the CL mutant light chain constant region CL SET1 (SEQ NO: 19) and CL SET2 (SEQ NO: 20). A 1+1 asymmetric anti-EGFRxcMet bispecific antibody cell line was constructed.

[0130] Table 5. EGFRxcMet bispecific antibody sequence information

[0131]

[0132]

[0133] The vector pCHO2.0-GS-Puro-H1-L1 containing the nucleotide sequence encoding the heavy chain (SEQ NO: 21) and the nucleotide sequence encoding the light chain (SEQ NO: 22) of the anti-c-Met antibody and the vector pCHO2.0-GS-Puro-H2-L2 containing the nucleotide sequence encoding the heavy chain (SEQ NO: 23) and the nucleotide sequence encoding the light chain (SEQ NO: 24) of the anti-EGFR antibody were co-transfected into the host cell CHOS-ADP Fut8KO (defucosylation gene knockout cell line) by electroporation transfection. The cells were screened under pressure with Puromycin and MSX screening pressure to obtain a high-yield minipool, and then a round of limiting dilution and monoclonal identification was performed to obtain a high-yield stable clone cell line. By comparing the growth status, protein expression level and physicochemical properties of the cloned protein, the cloned cell line 6F5 was finally determined to be a recombinant engineering cell line.

[0134] Dynamis AGT Medium was used as the basic culture medium, with an inoculation density of (1.0±0.2)×106cells / ml. On the 3rd, 5th, 7th, 9th, and 11th days, 5.0±0.5% (w / w) of the initial culture weight of 7a feed was added, and 0.5±0.05% (w / w) of the initial culture weight of 7b was added. The dissolved oxygen was set at 40%, the initial culture temperature was 36.5°C, and the temperature was lowered to 33.0°C on the 4th day. Every day, according to the glucose concentration test results, 300g / kg of glucose concentrate was added to make the glucose concentration in the cell fluid reach 6.0g / L, except on the day of harvest. The culture was terminated when the cell viability was less than 80% on the 14th day. During the culture process, Vicell (Beckman) was used to detect the cell density and viability. Starting from the 7th day, Cedex (Roche) was used to detect the antibody yield every day. The results are shown in Table 4, and the expression level of the bispecific antibody reached 2.432g / L.

[0135] The supernatant was collected and the target protein was purified by protein A magnetic beads (purchased from GenScript) sorting method. The magnetic beads were resuspended in an appropriate volume of binding buffer (PBS + 0.1% Tween 20, pH 7.4) (1-4 times the volume of the magnetic beads) and added to the sample to be purified. Incubate at room temperature for 1 hour with gentle shaking during the period. The sample was placed on a magnetic stand (purchased from Beaver), the supernatant was discarded, and the magnetic beads were washed 3 times with binding buffer. Elution buffer (0.1M sodium citrate, pH 3.2) was added according to 3-5 times the volume of the magnetic beads. Oscillate at room temperature for 5-10 minutes, put back on the magnetic stand, collect the elution buffer, transfer to the collection tube to which neutralization buffer (1M Tris, pH 8.54) has been added, and mix well to obtain the bispecific antibody sample EGFRxcMET-1.

[0136] The purity of the protein was obtained by HPLC. The HPLC method was as follows: mobile phase: 150 mM Na2HPO4·12H2O, pH 7.0. Chromatographic conditions: detection wavelength 280 nm, column temperature 25 °C, flow rate 0.5 ml / min, detection time: 30 min, TSK gelG3000SWXL column. The SEC results are as follows: Figure 1 A shows that the purity of the bispecific antibody obtained by one-step affinity purification is 98.18%.

[0137] The heavy and light chain pairing of the protein was obtained by high performance liquid chromatography mass spectrometry. The instruments used were liquid phase system Vanquish UHPLC (Thermo), mass spectrometer Q Exactive (Thermo) and chromatographic column Waters ACQUITY UPLC BEHC4, 2.1 mm × 10 mm. Take 50 μg of sample, add ultrapure water to dilute to 25 μl, centrifuge and take 20 μl of sample to 10 injection bottles, inject 5 μl, and use LC-MS to analyze the intact molecular weight. The chromatographic conditions are: column temperature: 80 ° C; UV detection wavelength: 280 nm; flow rate: 0.3 mL / min; mobile phase A: aqueous solution (containing 0.1% formic acid); mobile phase B: acetonitrile solution (containing 0.1% formic acid). Mass spectrometry parameters are: ESI ion source: ion transfer tube temperature 320 ° C, voltage 3.8 kV, gas flow rate 36 L / min; mode: positive ion FullMS; resolution: 17500; scanning range: 600-4000 m / z. The results are as follows Figure 1 As shown in B, the ratio of correctly paired products of the purified bispecific antibodies was >98%.

[0138] Example 2. Preparation of anti-EGFRxc-Met bispecific antibody injection

[0139] Using citric acid-sodium citrate (abbreviated as: CA) buffer, bispecific antibody liquid preparations with concentrations of 5, 10, 15, 20, 25, 30, 35, 40, 45, and 50 mg / mL are prepared, and sucrose can be optionally added.

[0140] Table 6. EGFRxcMet bispecific antibody injection composition

[0141] Element Final concentration EGFRxcMET-1 5, 10, 15, 20, 25, 30, 35, 40, 45, 50mg / mL Citrate-sodium citrate buffer 10mM sucrose 40mg / mL

[0142] Prepare 1 kg of 10 mM citric acid-sodium citrate buffer, weigh 0.282 g of citric acid monohydrate (C6H8O7·H2O), 2.547 g of sodium citrate dihydrate (C6H5Na3O7·2H2O), add water to 1 kg, and filter the buffer. By dialysis, EGFRxcMET-1 was replaced in the 10 mM citric acid-sodium citrate buffer prepared above, and sucrose mother solution was added to prepare the target formulation, with protein concentrations of 5, 10, 15, 20, 25, 30, 35, 40, 45, and 50 mg / mL. After filtering with a 0.22 μm PVDF filter membrane in a biological safety cabinet, the mixture was dispensed into vials, stoppered, and capped to prepare a bispecific antibody injection.

[0143] Example 3. Binding activity of anti-EGFRxc-Met bispecific antibody to EGFR and c-Met positive tumor cells

[0144] A375 cells are human malignant melanoma cells purchased from (Addexbio) and have low expression of EGFR and c-Met receptors. H292 cells are human lung adenocarcinoma cells purchased from (procell) and have high expression of EGFR and c-Met receptors. HCC827 cells are human non-small cell lung cancer cells purchased from (Chinese Academy of Sciences Collection Cell Bank) and have high expression of EGFR and c-Met receptors. The expanded cultured cells were adjusted to an appropriate cell density and added to a 96-well flow plate. After centrifugation, the gradient diluted samples to be tested were added and incubated at 4°C for 1h. Wash twice with PBS, add the corresponding fluorescent secondary antibody diluted to the appropriate concentration, incubate at 4°C for 30min, and wash twice with PBS. Add PBS to resuspend the cells, detect on the CytoFlex flow cytometer and calculate the corresponding MFI.

[0145] For tumor cells with different EGFR and MET expression peaks, the EGFRxc-Met bispecific antibody candidate EGFRxcMET-1 showed strong cell binding activity antibody, with a binding strength of EC 50 The specific values ​​are shown in Table 7.

[0146] Table 7. Antibody binding activity to tumor cells

[0147] <![CDATA[A375EC 50 (nM)]]> <![CDATA[H292EC 50 (nM)]]> <![CDATA[HCC827EC 50 (nM)]]> EGFRxcMET-1 1.35 2.34 3.67

[0148] Example 4. Anti-EGFRxc-Met bispecific antibody induces ADCC effect

[0149] A375 cells are human malignant melanoma cells purchased from (Addexbio) and express EGFR and c-Met receptors. H1975 cells are human lung adenocarcinoma cells purchased from (Addexbio) and highly express EGFR and c-Met receptors. HCC827 cells are human non-small cell lung cancer cells purchased from (Chinese Academy of Sciences Collection Cell Bank) and highly express EGFR and c-Met receptors. The expanded cultured A375 / H1975 / HCC827 cells were resuspended in 1640 medium at a cell density of 1.2x10 6 cells / ml; CD16a-NFAT-Luc Jurkat reporter gene cells (self-made, CD16a and NFAT-Luc gene sequences were constructed on the pCDNA3.1 vector, then transfected into Jurkat cells, and CD16a-NFAT-LucJurkat reporter gene cells were obtained by antibiotic resistance pressure screening) were resuspended in 1640 medium and the cell density was adjusted to 6x10 6 cells / mlcells / ml; dilute the antibody to 300nM with 1640 culture medium, then perform 4-fold gradient dilution, add 25ul of the gradient diluted antibody to each well of a 96-well cell culture plate, and add 25ul of the target cells to each well, mix and incubate at room temperature for 30min, then add 25ul of the effector cells to each well, mix and culture at 37°C, 5% CO2 for 6h, then add 75ul of Bio-turbo reagent (purchased from Ruian) to each well, mix and collect chemiluminescent signals with an enzyme reader.

[0150] The EGFRxc-Met bispecific antibody EGFRxMET-1 induced ADCC effect and showed dependence on the amount of antigen expression (HCC827>H1975>A375).

[0151] Example 5. Tumor inhibitory effect of different doses of EGFRxc-Met bispecific antibody in H292 tumor-bearing CB-17 SCID mouse model

[0152] In this study, human lung cancer cells were subcutaneously inoculated into CB-17SCID mice. The tumor-bearing model was established by subcutaneously inoculating human lung cancer cells H292 (highly expressing EGFR / c-MET) in mice, which can be used to evaluate the anti-tumor and safety characteristics of the test article in the disease state. This study was divided into 4 groups, with 6 mice in each group, and PBS and 3 different doses (2, 8, and 32 mg / kg) of EGFRxcMET-1 were intraperitoneally injected once every 4 to 6 days, for a total of 3 times. The growth inhibitory effect and safety of different doses of bispecific antibodies on the human lung cancer cell H292 tumor model inoculated subcutaneously in CB-17SCID mice were investigated.

[0153] The tumors of mice in the negative control PBS group grew rapidly, and the average tumor volume reached 900mm at the end of the experiment (D30). 3 The above results indicate that the tumor model was successfully established in this experiment.

[0154] At the end of the experiment, the tumor volumes of the PBS group and the 2, 8, and 32 mg / kg EGFRxcMET-1 groups were 930.82 mm 3 、587.42mm 3 (P<0.05), 65.03mm 3 (P<0.0001), 45.35 mm 3 (P<0.0001). Compared with the negative control PBS group, each dose group of EGFRxcMET-1 can inhibit tumor growth in a dependent manner, with TGI of 45%, 113% and 115%, respectively, and tumor weights of 0.53g, 0.30g (P<0.01), 0.03g (P<0.0001), and 0.01g (P<0.0001), respectively. The results are shown in Table 8. There was no abnormality in the state of mice in each group; compared with the control group, the weight of mice in each drug-treated group did not decrease significantly; at the end of the experiment, no obvious abnormality was found in the main organs of mice in each group of gross anatomy, indicating that the drugs in each group did not produce obvious toxicity to mice at the dosage used in this experiment.

[0155] Table 8. Effects of each treatment group on the volume, weight and TGI of H292 subcutaneous transplanted tumors at the end point of the experiment (D30)

[0156]

[0157] Note: Compared with PBS group, "NS" P>0.05; "*" P<0.05; "**" P<0.01; "****" P<0.0001

[0158] Example 6. Study on the growth inhibitory effect of combined use of osimertinib on the H1975-HGF tumor model inoculated subcutaneously in NOD / SCID mice

[0159] In this study, a tumor model was established by subcutaneously inoculating H1975-HGF (highly expressing EGFR (T790M / L858R), c-MET) human lung cancer cells in NOD / SCID mice. This model can be used to evaluate the anti-tumor effects related to the mechanism of action of the test article and the safety characteristics under the disease state. This study was divided into 6 groups, with 6 mice in each group, and they were intraperitoneally injected with PBS, 3mg / kg rivrevant, 3mg / kg EGFRxcMET-1, 3mg / k osimertinib, 3mg / kg rivrevant combined with 3mg / kg osimertinib, and 3mg / kg EGFRxcMET-1 combined with 3mg / kg osimertinib. Osimertinib was administered once a day for a total of 6 times; EGFRxcMET-1 / rivrevant was administered once every 2 days, The drug was administered twice. Effect of osimertinib on H1975 cells in NOD / SCID mice injected subcutaneously -HGF tumor model growth inhibition and its safety.

[0160] Taking into account the results of the endpoint tumor volume, TGI index and tumor weight, 1 / 6 tumors in the EGFRxcMET-1 combined with osimertinib group regressed, while no tumors in other groups regressed. The tumor inhibition effect of EGFRxcMET-1 combined with osimertinib was significantly stronger than that of the two single drugs, showing a good combined synergistic effect; and the tumor inhibition effect of EGFRxcMET-1 combined with osimertinib was better than that of ervantumab combined with osimertinib.

[0161] Table 9. Effects of each treatment group on H1975-HGF tumor volume, weight and TGI

[0162]

[0163] Note: Compared with the PBS group, “NS” P>0.05; “*” P<0.05; “**” P<0.01; “***” P<0.001; “****” P<0.0001; N / A No statistical analysis was performed.

[0164] Example 7. In vivo pharmacodynamic study of Ba / F3EGFR D770-N771ins_SVD nude mouse subcutaneous transplant tumor model

[0165] In the subcutaneous xenograft tumor model of mouse proto-B cells Ba / F3EGFR D770-N771ins_SVD nude mice containing EGFR exon 20 insertion mutation, 10 mg / kg of ervantumab, 3 and 10 mg / kg of EGFRxcMET-1 were administered by intraperitoneal injection twice a week for 2 consecutive weeks (a total of 4 times), and the corresponding tumor inhibition rates TGI were 53.35%, 49.23%, and 58.41%, respectively. At the same dose (10 mg / kg), the tumor inhibition effect of EGFRxcMET-1 was comparable to that of ervantumab, and all animals tolerated it well.

[0166] Table 10. Evaluation of anti-tumor efficacy in Ba / F3EGFR-D770-N771ins_SVD xenograft tumor model

[0167] Group <![CDATA[Tumor volume (mm 3 )]]> T / C(%) TGI (%) p-value Vehicle (Solvent Control) 1003.01±64.41 - - - Human IgG Control 1087.45±121.15 108.42 -9.46 - Evantamab (10 mg / kg) 523.49±75.01 52.19 53.35 <0.0001 EGFRxcMET-1 (3 mg / kg) 559.94±35.20 55.83 49.23 <0.0001 EGFRxcMET-1 (10 mg / kg) 478.67±51.79 47.72 58.41 <0.0001

[0168] Example 8. In vivo pharmacodynamic study of Ba / F3EGFR-Del19 / T790M / C797S nude mouse subcutaneous transplant tumor model

[0169] In the subcutaneous xenograft tumor model of Ba / F3EGFR-Del19 / T790M / C797S nude mice with triple EGFR mutations, 10 mg / kg of ervantumab, 3, 10 and 30 mg / kg of EGFRxcMET-1 were administered by intraperitoneal injection twice a week for 2 consecutive weeks (4 times in total), and the corresponding tumor inhibition rates TGI were 97.17%, 75.81%, 96.57% and 121.57%, respectively. EGFRxcMET-1 has a significant tumor inhibition effect and shows a good dose-effect relationship. The same dose (10 mg / kg) has a tumor inhibition effect comparable to that of ervantumab, and all animals tolerate it well.

[0170] Table 11. Evaluation of anti-tumor efficacy in Ba / F3EGFR-Del19 / T790M / C797S xenograft tumor model

[0171] Group <![CDATA[Tumor volume (mm 3 )]]> T / C(%) TGI (%) p-value Vehicle (Solvent Control) 1164.27±113.75 - - - Human IgG Control 1465.20±355.09 125.85 -28.61 - Evantamab (10 mg / kg) 141.03±30.79 12.11 97.17 <0.0001 EGFRxcMET-1 (3 mg / kg) 366.75±45.00 31.50 75.81 <0.0001 EGFRxcMET-1 (10 mg / kg) 148.85±23.91 12.78 96.57 <0.0001 EGFRxcMET-1 (30 mg / kg) 87.35±9.81 7.50 121.57 <0.0001

[0172] Example 9. In vivo pharmacodynamic study of ametinib combined with human non-small cell lung cancer PC-9 cell line derived nude mouse subcutaneous transplant tumor model

[0173] This study evaluated the synergistic antitumor effect of the combination therapy of EGFRxc-Met bispecific antibody and ametinib in a nude mouse subcutaneous xenograft tumor model derived from the non-small cell lung cancer PC-9 cell line containing EGFR exon 19 deletion mutation.

[0174] PC-9 cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum and 1% penicillin-streptomycin in a 37°C, 5% CO2 incubator. After the cells were fully grown, they were subcultured and the cells in the logarithmic growth phase were collected and counted. The cells were resuspended in PBS to a final concentration of 5.0×10 7 cells / mL and then inoculated. 0.1mL PC-9 cell suspension (containing 5x10 6 The tumor growth was observed and the animals were randomly divided into groups according to the tumor volume and weight. The average tumor volume was 328 mm 3 The day of drug administration was defined as Day 1. The remaining animals were euthanized at the end of the experiment. This experiment was divided into 5 groups, with 1 animal in each group. The experimental design was as follows:

[0175] Table 12. Experimental design of PC-9 nude mouse subcutaneous xenograft tumor model

[0176]

[0177] a. Dosage volume: 10 μl / g based on mouse body weight. If the body weight decreases by more than 15%, the dosing regimen should be adjusted accordingly;

[0178] bpo: oral administration; ip: intraperitoneal administration;

[0179] c.qd: once a day; biw: twice a week.

[0180] The mice in the Vehicle solvent control and IgG control groups were euthanized on the 29th day after continuous administration; the EGFRxcMET-1 group was euthanized on the 60th day after continuous administration; the ametinib group and the two-drug combination group were discontinued after 90 days of continuous administration, and euthanized on the 65th day after discontinuation of the drug. The tumor volume data at each time point in each group are expressed as the mean and standard error (SEM). Based on the tumor volume data at different time points in each group, Dunnett's multiple comparisons test in Two-way or One-way ANOVA was used to analyze the differences between the groups. All data analyses were performed using GraphPad Prism 9, and p<0.05 was considered to be significantly different. The tumor inhibition rate of mice in each group on Day 22 after administration is shown in Table 13, and the tumor inhibition rate of mice in each group at the efficacy endpoint is shown in Table 14.

[0181] Table 13. Evaluation of the anti-tumor efficacy of the combination of bispecific antibodies and ametinib on PC-9 xenograft tumor model (22 days after administration)

[0182] Grouping <![CDATA[Tumor volume (mm 3 )]]> T / C(%) TGI (%) p-value Vehicle (Solvent Control) 1510.99±154.57 - - - IgG control 1484.97±144.64 98.28 2.25 - EGFRxcMET-1(10mpk) 184.00±25.71 12.18 112.32 <0.0001 Ametinib (10mpk) 18.79±2.66 1.24 194.28 <0.0001 EGFRxcMET-1+Ametinib 12.60±1.35 0.83 196.17 <0.0001

[0183] Note: The data in the table are all from the 22nd day.

[0184] Table 14. Evaluation of the anti-tumor efficacy of the combination of bispecific antibodies and ametinib in the PC-9 xenograft tumor model (efficacy endpoint on day 155)

[0185]

[0186] Note: The data in the table are all the endpoints of the efficacy of each group on the 155th day

[0187] The efficacy evaluation of the ametinib monotherapy group and the EGFRxcMET-1 + ametinib combination group ended on Day 155, and the mouse tumors were removed and photographed. In the ametinib monotherapy group, after 3 weeks of administration, the average tumor volume was 18.79 mm 3 , TGI was 194.28%, and the average tumor volume of the whole group continued to shrink. From the 78th day, the average tumor volume was less than 2mm 3 , 7 mice tumors completely disappeared. After drug withdrawal, the tumors that had disappeared in the ametinib monotherapy group recurred and continued to grow. The average tumor volume at the efficacy endpoint reached 903.91mm 3 , and among the 7 mice whose tumors had completely regressed before, 4 relapsed and 7 mice had tumor burden at the efficacy endpoint (7 / 10). For the EGFRxcMET-1+Ametinib combination group, after 3 weeks of continuous administration, the average tumor volume was 12.60mm 3 , TGI was 196.17%, and the average tumor volume of the whole group continued to shrink. From the 78th day, the average tumor volume was less than 1mm 3 , 9 mice had completely regressed tumors. After drug withdrawal, only 3 mice had tumor recurrence, but the size of the tumors remained at 5mm 3 The average tumor volume of the combined group was 111.77 mm 3 In the whole group, only one mouse was tumor-bearing (1 / 10). The tumor volumes of each group at different time points were as follows: Figure 2 shown.

[0188] EGFRxcMET-1 has a significant tumor-suppressing effect on the nude mouse subcutaneous xenograft tumor model derived from the human non-small cell lung cancer PC-9 cell line containing EGFR exon 19 deletion mutation. Compared with the EGFRxcMET-1 monotherapy group, the combination of EGFRxcMET-1+Ametinib significantly enhanced the tumor inhibition effect; compared with the Ametinib monotherapy group, the combination of EGFRxcMET-1+Ametinib significantly delayed the recurrence and growth of tumors.

[0189] Example 10. Phase I clinical study of the safety, tolerability, pharmacokinetics and efficacy of EGFRxc-Met bispecific antibody in patients with advanced solid tumors

[0190] 1. Research objectives

[0191] To evaluate the safety and tolerability, PK characteristics, efficacy, immunogenicity, and other safety indicators of EGFRxcMET-1 in subjects with locally advanced or metastatic NSCLC with EGFR mutations. To evaluate the efficacy, safety, PK characteristics, immunogenicity, and other efficacy indicators of EGFRxcMET-1 in subjects with advanced solid tumors.

[0192] 2. Study Drugs

[0193] The tested drug is EGFRxcMET-1 injection, the sequence of which is SEQ ID NO: 21-24 in the present invention. Dosage form: injection, specification: 10 ml: 200 mg / vial. The research drugs used in this experiment were provided by Shanghai Hansen Biopharmaceutical Technology Co., Ltd.

[0194] 3. Dosage regimen

[0195] The dose escalation trial will give target subjects intravenous EGFRxcMET-1 treatment. The dose escalation will start from the preset starting dose of 400 mg and increase in sequence to 400 mg, 800 mg, 1200 mg, 1600 mg, and 2000 mg.

[0196] Dosing regimen for the Q2W group: Subjects were given intravenous drip once a week starting from day 1 of cycle 1 (C1D1), and once every 2 weeks starting from cycle 2, with a treatment cycle of 4 weeks. For the 400mg dose group, the first dose was given on C1D1; for the 800mg and above dose groups, the first dose was given on C1D1 and C1D2, with 400mg given on C1D1 and the remaining dose given on C1D2. The second dose and subsequent doses do not need to be given in divided doses.

[0197] Q3W group dosing regimen: subjects were given intravenous drip once a week on C1D1, C1D8, C1D15, and C2D1, and then once every 3 weeks. Each 3-week treatment cycle was a treatment cycle. The first dose was given on C1D1 and C1D2, 400 mg on C1D1, and the remaining dose on C1D2. The second dose and subsequent doses did not need to be divided into multiple doses.

[0198] 4. Inclusion criteria

[0199] Phase Ia: Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC who have failed or are intolerant to standard treatment or are unable to obtain standard treatment and carry EGFR activating mutations.

[0200] Phase Ib: Cohort 1 is for subjects with locally advanced or metastatic NSCLC who have failed or are intolerant to platinum-based chemotherapy and carry EGFRExon20ins mutations and have been confirmed by histology or cytology. Cohort 2 is for other advanced solid tumors who have failed or are intolerant to standard treatment confirmed by histology or cytology.

[0201] 5. Clinical trial results

[0202] Of all the 19 subjects enrolled, 14 subjects underwent dose escalation studies (1 in the 400 mg Q2W group, 3 in the 800 mg Q2W group, 4 in the 1200 mg Q2W group, and 6 in the 1600 mg Q2W group), and 5 subjects underwent dose expansion studies (4 in the 800 mg Q2W group and 1 in the 2000 mg Q3W group).

[0203] Dose escalation in four dose groups has been completed, and no dose-limiting toxicity (DLT) events have been observed. The maximum tolerated dose (MTD) of EGFRxcMET-1 has not been reached. Among the 16 subjects whose efficacy could be evaluated, 1 subject had PR, 8 subjects had SD (5 subjects had target lesions reduced), and the DCR was 56.3%.

[0204] In summary, the current research results show that EGFRxcMET-1 has an anti-tumor effect in subjects with advanced EGFR activating mutation NSCLC who have failed or are intolerant to previous standard treatment, and preliminary anti-tumor activity was observed in all dose groups.

[0205] Example 11. Phase Ib / III clinical study on the safety, efficacy, pharmacokinetics and immunogenicity of EGFRxc-Met bispecific antibody combined with ametinib mesylate tablets in patients with advanced non-squamous non-small cell lung cancer

[0206] 1. Research objectives

[0207] To evaluate the efficacy, safety, tolerability, PK characteristics and immunogenicity of different dose levels of EGFRxcMET-1 combined with ametinib in subjects with advanced non-squamous NSCLC harboring EGFR mutations who have not received systemic anti-tumor treatment.

[0208] 2. Study Drugs

[0209] The tested drug is EGFRxcMET-1 injection, listed as SEQ ID NO: 21-24 in the present invention. Dosage form: injection, specification: 10ml: 200mg / vial. The research drugs used in this experiment were provided by Shanghai Hansen Biopharmaceutical Technology Co., Ltd.

[0210] The test drug is ametinib mesylate tablets, dosage form: tablets, specification: 55 mg / tablet. The research drugs used in this trial were provided by Shanghai Hansen Biopharmaceutical Technology Co., Ltd.

[0211] 3. Dosage regimen

[0212] Two doses of EGFRxcMET-1 injection (800mg; 1200mg) are administered by intravenous drip once a week starting from C1D1, and once every 2 weeks starting from the second cycle. Each 4-week treatment cycle is a treatment cycle. The first dose is administered on C1D1 and C1D2, 400mg is administered on C1D1, and the remaining dose is administered on C1D2. The second dose and subsequent doses do not need to be administered in divided doses.

[0213] Ametinib was taken orally at a dose of 110 mg once a day starting from C1D1, with one treatment cycle consisting of 4 weeks.

[0214] 4. Inclusion criteria

[0215] Locally advanced or metastatic non-squamous NSCLC confirmed by histology or cytology, must carry EGFR sensitive mutations (L858R mutation and / or exon 19 deletion mutation), either single mutation or combined with other EGFR mutations. Subjects must not have received systemic anti-tumor therapy and pulmonary palliative treatment in the advanced stage.

[0216] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes may be made to the details according to all the teachings that have been published, and these changes are within the scope of protection of the present invention. The entire invention is given by the attached claims and any equivalents thereof.

Claims

1. Use of a bispecific antibody in the preparation of a drug for preventing or treating cancer, wherein the bispecific antibody comprises a first antibody or antigen-binding fragment targeting a first target c-Met, and a second antibody or antigen-binding fragment targeting a second target EGFR; wherein the first antibody or antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO:01, HCDR2 as shown in SEQ ID NO:02, HCDR3 as shown in SEQ ID NO:03; and LCDR1 as shown in SEQ ID NO:04, LCDR2 as shown in SEQ ID NO:05, LCDR3 as shown in SEQ ID NO:06; The second antibody or antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO:09, HCDR2 as shown in SEQ ID NO:10, HCDR3 as shown in SEQ ID NO:11; and LCDR1 as shown in SEQ ID NO:12, LCDR2 as shown in SEQ ID NO:13, and LCDR3 as shown in SEQ ID NO:

14.

2. The use according to claim 1, wherein the c-Met binding domain of the bispecific antibody is a Fab region formed by a first heavy chain and a first light chain, the EGFR binding domain is a Fab region formed by a second heavy chain and a second light chain, and the first heavy chain and the second heavy chain are combined with each other to form a heterodimer Fc region.

3. Use of a bispecific antibody pharmaceutical composition in the preparation of a medicament for preventing or treating cancer, wherein the pharmaceutical composition comprises the bispecific antibody according to claim 1 or 2 and one or more pharmaceutically acceptable excipients, diluents or carriers.

4. The use according to any one of claims 1 to 3, wherein the bispecific antibody or bispecific antibody pharmaceutical composition is used in combination with an EGFR inhibitor.

5. The use according to claim 4, wherein the EGFR inhibitor is selected from erlotinib, gefitinib, befotertinib, osimertinib, almonertinib, furmonertinib, oritinib, rezetinib, avitinib, olmutinib, rociletinib; preferably almonertinib and osimertinib.

6. The use according to any one of claims 1 to 5, wherein the first antibody or antigen-binding fragment comprises a heavy chain variable region as shown in SEQ ID NO: 07, and a light chain variable region as shown in SEQ ID NO: 08; the second antibody or antigen-binding fragment comprises a heavy chain variable region as shown in SEQ ID NO: 15, and a light chain variable region as shown in SEQ ID NO:

16.

7. The use according to any one of claims 1 to 6, wherein the first antibody or antigen-binding fragment comprises a heavy chain as shown in SEQ ID NO: 21 and a light chain as shown in SEQ ID NO: 22; the second antibody or antigen-binding fragment comprises a heavy chain as shown in SEQ ID NO: 23 and a light chain as shown in SEQ ID NO:

24.

8. The use according to any one of claims 1 to 7, wherein the bispecific antibody or bispecific antibody pharmaceutical composition and the EGFR inhibitor are contained in different preparations as active ingredients, respectively, and are administered simultaneously, concurrently, sequentially, continuously, alternately or separately.

9. The use according to any one of claims 1 to 8, wherein the cancer is selected from solid tumors, preferably advanced solid tumors.

10. The use according to any one of claims 1 to 9, wherein the cancer is a cancer expressing c-Met and / or EGFR.

11. The use according to claim 10, wherein the cancer expressing c-Met and / or EGFR is mediated by wild-type EGFR, EGFR activating mutations, EGFR gene amplification, elevated levels of circulating HGF, wild-type c-Met, c-Met activating mutations, c-Met gene amplification, MET gene amplification, or mutant KRAS, preferably mediated by EGFR activating mutations and MET gene amplification.

12. The use according to claim 11, wherein the EGFR activating mutation comprises at least one mutation selected from the group consisting of: L718Q, L718V, G719A, G719S, G719C, G719D, L858R, L858P, L861Q, G724S, E746K, L747S, E749Q, A750P, A755V, V765M, C797S, S768I or T790M substitution; deletion of E746-A750; deletion of R748-P753; insertion of Ala (A) between M766 and A767; insertion of Ser, Val and Ala (SVA) between S768 and V769; insertion of Asn and Se between P772 and H773 Insertion of one or more amino acids between D761 and E762, between A763 and Y764, between Y764 and Y765, between M766 and A767, between A767 and V768, between S768 and V769, between V769 and D770, between D770 and N771, between N771 and P772, between P772 and H773, between H773 and V774, and between V774 and C775; deletion of one or more amino acids in EGFR exon 19; or insertion of one or more amino acids in EGFR exon 19; deletion of one or more amino acids in EGFR exon 20; or insertion of one or more amino acids in EGFR exon 20.

13. The method of claim 1 , wherein the cancer is selected from epithelial cell cancer, breast cancer, ovarian cancer, lung cancer, rectal cancer, anal cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, pharyngeal cancer, nasal cancer, pancreatic cancer, skin cancer, oral cancer, tongue cancer, esophageal cancer, vaginal cancer, endometrial cancer, cervical cancer, spleen cancer, testicular cancer, gastric cancer, thymus cancer, colon cancer, thyroid cancer, liver cancer or melanoma, preferably lung cancer or liver cancer.

14. The use according to claim 12, wherein the cancer is non-small cell lung cancer (NSCLC), lung adenocarcinoma, lung squamous cell carcinoma, large cell lung cancer, small cell lung cancer, lung sarcomatoid carcinoma, hepatocellular carcinoma (HCC).

15. The use according to claim 14, wherein the cancer is non-squamous non-small cell lung cancer.

16. The use according to any one of claims 4 to 15, characterized in that: The dosage of the EGFR inhibitor is 10-500 mg, preferably 10-200 mg, more preferably 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg.

17. The use according to any one of claims 4 to 16, characterized in that: The EGFR inhibitor is administered twice a day, once a day, once every two days, once every three days, preferably once a day, once every two days.

18. The use according to any one of claims 3 to 17, characterized in that: The bispecific antibody pharmaceutical composition has a unit concentration of about 1 mg / mL to about 100 mg / mL, preferably about 5 mg / mL to about 50 mg / mL, and more preferably about 10 mg / mL to about 30 mg / mL.

19. The use according to any one of claims 3 to 18, characterized in that: The bispecific antibody pharmaceutical composition has a specification of 10 mL: 10 mg to 10 mL: 1000 mg per vial, preferably 10 mL: 100 mg to 10 mL: 500 mg, more preferably 10 mL: 100 mg, 10 mL: 200 mg, 10 mL: 300 mg, 10 mL: 400 mg or 10 mL: 500 mg.

20. The use according to any one of claims 1 to 19, characterized in that: The dosage of the bispecific antibody or bispecific antibody pharmaceutical composition is selected from about 100 mg to about 5000 mg, preferably 400 mg to about 2000 mg, and more preferably 400 mg, 800 mg, 1000 mg, 1200 mg, 1400 mg, 1600 mg, 1800 mg, and 2000 mg.

21. The use according to any one of claims 1 to 20, characterized in that: The administration frequency of the bispecific antibody or bispecific antibody pharmaceutical composition is once a day, once every two days, once every three days, twice a week, once a week, once every two weeks, once every three weeks, once a month, preferably once a week, once every two weeks, or once every three weeks.

22. The use according to claim 21, characterized in that: The administration frequency of the bispecific antibody or bispecific antibody pharmaceutical composition is: 1) Once a week in the first treatment cycle and once every two weeks from the second treatment cycle onwards, with each four weeks being a treatment cycle; or 2) The first treatment cycle is once a week, and the second treatment cycle is once every three weeks. Every three weeks is a treatment cycle.

23. A method for treating or preventing cancer, comprising administering the bispecific antibody or bispecific antibody pharmaceutical composition of any one of claims 1 to 22 to a subject in need thereof.

24. A method for treating or preventing cancer, the method comprising administering to a subject in need thereof a bispecific antibody or a bispecific antibody pharmaceutical composition as described in any one of claims 1 to 22 and an EGFR inhibitor as described in any one of claims 4 to 17 in combination, wherein the combined administration may be simultaneous, concurrent, sequential, continuous, alternating or separate administration.

25. The method according to claim 23 or 24, wherein the cancer is a solid tumor, preferably epithelial cell cancer, breast cancer, ovarian cancer, lung cancer, rectal cancer, anal cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, pharyngeal cancer, nasal cancer, pancreatic cancer, skin cancer, oral cancer, tongue cancer, esophageal cancer, vaginal cancer, endometrial cancer, cervical cancer, spleen cancer, testicular cancer, gastric cancer, thymus cancer, colon cancer, thyroid cancer, liver cancer or melanoma, more preferably non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, large cell lung cancer, small cell lung cancer, lung sarcomatoid cancer, hepatocellular carcinoma.

Images